Latest News in the pharma Industry

Research & Development

AstraZeneca and Takeda collaborate to develop and commercialise MEDI1341 for Parkinson’s disease

AstraZeneca and Takeda collaborate to develop and commercialise MEDI1341 for Parkinson’s disease

31 Aug 2017

MEDI1341 has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies.

Read more 
Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma

Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma

31 Aug 2017

ENDEAVOR study long-term data show Kyprolis and dexamethasone reduced the risk of death by 24% versus Velcade and dexamethasone.

Read more 
Lilly to file baricitinib resubmission to FDA before end of January 2018

Lilly to file baricitinib resubmission to FDA before end of January 2018

30 Aug 2017

Resubmission package will include new safety and efficacy data.

Read more 
FDA approves new antibacterial drug

FDA approves new antibacterial drug

30 Aug 2017

First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor.

Read more 
Krystal microplate enables development of drug testing assay

Krystal microplate enables development of drug testing assay

29 Aug 2017

Scientists at the NCBS using Krystal 384-well black microplates to produce a standard drug testing assay for Plasmodium vivax infection.

Read more 
Berg and AstraZeneca collaborate to identify new therapeutic targets to treat neurological disorders

Berg and AstraZeneca collaborate to identify new therapeutic targets to treat neurological disorders

28 Aug 2017

Collaboration to focus on a disease target in Parkinson's disease with Berg's Interrogative Biology technology.

Read more 
New Repatha data support lower LDL-C levels for high-risk cardiovascular patients

New Repatha data support lower LDL-C levels for high-risk cardiovascular patients

28 Aug 2017

No evidence of a leveling off of effect and no new safety concerns were identified in this analysis.

Read more 
Regeneron and Sanofi to present new analyses from Praluent injection trials

Regeneron and Sanofi to present new analyses from Praluent injection trials

27 Aug 2017

Presentations include results from ODYSSEY APPRISE, an open-label study in 16 European countries and Canada in patients with severe hypercholesterolemia at high cardiovascular risk.

Read more 
EC approves first oral short-course treatment for highly active relapsing multiple sclerosis

EC approves first oral short-course treatment for highly active relapsing multiple sclerosis

27 Aug 2017

Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years.

Read more 
FDA grants Priority Review to Genentech's emicizumab for Hemophilia A with inhibitors

FDA grants Priority Review to Genentech's emicizumab for Hemophilia A with inhibitors

24 Aug 2017

Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children.

Read more 
Novavax’ preclinical influenza nanoparticle study published in Vaccine

Novavax’ preclinical influenza nanoparticle study published in Vaccine

23 Aug 2017

Data suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults.

Read more 
Novartis and MMV launch patient trial in Africa for a novel compound against multidrug-resistant malaria

Novartis and MMV launch patient trial in Africa for a novel compound against multidrug-resistant malaria

23 Aug 2017

Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission.

Read more